Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC).

Tagawa, S.T.; Saran, Ankeeta; Akhtar, Naveed; Goel, Shom; Mileo, G.; Kung, Sophia; Beltran, Himisha; Milowsky, Mathew I.; Mazumdar, Madhu; Wright, J. J.; Nanus, David M.

doi:10.1200/jco.2011.29.15_suppl.e15165

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 Capecitabine, gemcitabine, and sorafenib combinations have also shown promise with 16 to 45% of patients responding to treatment, with a PFS of 6.1 to 11.0 months and an overall survival of 18.3 to 25.8 months. [53][54][55] Gemcitabine and sunitinib combinations have shown similar promise (response rate, 25%; PFS 5.8 months) in both retrospective analyses and early stage clinical trials. [56][57][58] Sunitnib and sorafenib have also been added to gemcitabine and doxorubicin in patients with sarcomatoid RCC with response rates of up to 60%.…”

Section: Chemotherapy Plus Targeted Therapiesmentioning

confidence: 97%

Immunologics and Chemotherapeutics for Renal Cell Carcinoma

Diamond¹,

Riches

Faltas³

et al. 2014

Semin intervent Radiol

View full text Add to dashboard Cite

Treatment of metastatic renal cell carcinoma remains a challenge for clinicians. Traditional chemotherapy is ineffective and immunotherapy with interleukin-2 is only occasionally beneficial. The development of numerous agents targeting vascular endothelial growth factor and mammalian target of rapamycin signaling pathways that have been studied in phase III trials have resulted in significant improvement in survival for patients with clear cell renal cell carcinoma. Currently available U.S. Food and Drug Administration-approved first line targeted agents include sunitinib, pazopanib, temsirolimus, and bevacizumab (with interferon), while axitinib, everolimus, and sorafenib are most extensively used following progression as second- or third line therapy. Attempts to augment the activity of these agents by combining them together or with chemotherapy or immunotherapy have not yet proven to improve outcomes. As a result, the sequential use of single agents remains the current standard of care.

show abstract